Premium
Solid Biosciences Inc (SLDB)
NASDAQ
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for ... Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid's mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit https://www.solidbio.com. Show more
- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy...
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.66 | -12.890625 | 5.12 | 5.19 | 4.45 | 271999 | 4.83306279 | CS |
| 4 | -0.4311 | -8.81396822801 | 4.8911 | 6.11 | 4.45 | 294478 | 5.19239836 | CS |
| 12 | -3.26 | -42.2279792746 | 7.72 | 7.97 | 4.45 | 297278 | 5.81733265 | CS |
| 26 | -3.35 | -42.8937259923 | 7.81 | 10.37 | 4.45 | 387223 | 6.76155537 | CS |
| 52 | -0.73 | -14.0655105973 | 5.19 | 15.05 | 4.45 | 330065 | 7.73202887 | CS |
| 156 | -23.59 | -84.0998217469 | 28.05 | 30.45 | 1.81 | 372375 | 10.97704187 | CS |
| 260 | -62.14 | -93.3033033033 | 66.6 | 173.7 | 1.81 | 829422 | 49.20957421 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
